November 30, 2016 - By Hazel Jackson · 0 Comments
The stock of Cytosorbents Corporation (NASDAQ:CTSO) registered an increase of 2.94% in short interest. CTSO’s total short interest was 627,700 shares in November as published by FINRA. Its up 2.94% from 609,800 shares, reported previously. With 58,200 shares average volume, it will take short sellers 11 days to cover their CTSO’s short positions. The short interest to Cytosorbents Corporation’s float is 3.15%. The stock last traded at $5.1 per share. It is down 12.58% since April 27, 2016 and is uptrending. It has outperformed by 7.36% the S&P500.
CytoSorbents Corporation is a critical care focused immunotherapy company. The company has a market cap of $126.18 million. The Firm is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. It currently has negative earnings. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Insitutional Activity: The institutional sentiment increased to 1.78 in 2016 Q2. Its up 0.99, from 0.79 in 2016Q1. The ratio improved, as 7 funds sold all Cytosorbents Corp shares owned while 7 reduced positions. 4 funds bought stakes while 7 increased positions. They now own 1.36 million shares or 2.40% less from 1.40 million shares in 2016Q1.
Barclays Plc reported 4 shares or 0% of all its holdings. Blackrock Fund Advsrs has 53,915 shares for 0% of their US portfolio. Blackrock Institutional Tru Na holds 26,460 shares or 0% of its portfolio. Creative Planning accumulated 0% or 5,500 shares. Pnc Fin Ser Grp Inc reported 10,200 shares or 0% of all its holdings. Northern Tru, a Illinois-based fund reported 23,709 shares. Deutsche Comml Bank Ag, a Germany-based fund reported 75 shares. Royal Financial Bank Of Canada holds 0% or 800 shares in its portfolio. Jpmorgan Chase & accumulated 2,042 shares or 0% of the stock. Skylands Cap Limited Liability Corporation holds 0.04% or 48,350 shares in its portfolio. Glenmede Tru Na has 19,008 shares for 0% of their US portfolio. Susquehanna Interest Group Ltd Liability Partnership, a Pennsylvania-based fund reported 22,848 shares. State Street holds 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO) for 12,000 shares. Bancshares Of Ny Mellon has invested 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO). The North Carolina-based Savings Bank Of America De has invested 0% in Cytosorbents Corp (NASDAQ:CTSO).
Insider Transactions: Since June 7, 2016, the stock had 2 insider purchases, and 0 insider sales for $39,090 net activity. On Wednesday, August 24 Chan Phillip P. bought $24,450 worth of the stock or 5,000 shares. $14,640 worth of shares were bought by BATOR MICHAEL G. on Tuesday, June 7.
Out of 4 analysts covering CytoSorbents (NASDAQ:CTSO), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. CytoSorbents has been the topic of 4 analyst reports since October 29, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Aegis Capital given on Wednesday, October 26. As per Friday, October 7, the company rating was initiated by B. Riley & Co. The company was initiated on Tuesday, May 24 by Maxim Group. The firm has “Buy” rating given on Thursday, October 29 by WBB Securities.
CytoSorbents Corporation, incorporated on April 25, 2002, is a critical care focused immunotherapy company. The Firm is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.
More notable recent Cytosorbents Corp (NASDAQ:CTSO) news were published by: Marketwatch.com which released: “Cytosorbents Corp.” on April 21, 2011, also Fool.com with their article: “Why Cytosorbents Corp Shares Burst Today” published on April 01, 2015, Prnewswire.com published: “First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using …” on November 22, 2016. More interesting news about Cytosorbents Corp (NASDAQ:CTSO) were released by: Prnewswire.com and their article: “CytoSorbents Advances War On Sepsis with Development of CytoSorb-XL” published on September 08, 2016 as well as Prnewswire.com‘s news article titled: “CytoSorbents to Present at the 2016 Rodman & Renshaw Annual Global Investment …” with publication date: September 07, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Hazel Jackson